MedTrace Logo

In Vitro Activity of Ceftolozane-tazobactam Against Contemporary Nosocomial Gram "-" Pathogens Isolated in Russia

NCT04679610 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2020-12-22

No results posted yet for this study

Summary

Infections caused by resistant gram-negative bacteria are becoming increasingly prevalent and now constitute a serious threat to public health worldwide because they are difficult to treat and are associated with high morbidity and mortality rates. Among nosocomial infections, the most major threat represent infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative pathogens.

Conditions

  • Nosocomial Infection

Sponsors & Collaborators

  • The Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC)

    lead OTHER

Eligibility

Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2020-04-01
Completion
2020-12-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04679610 on ClinicalTrials.gov